company background image
FRE logo

Fresenius SE KGaA XTRA:FRE Stock Report

Last Price

€33.89

Market Cap

€19.0b

7D

0.06%

1Y

19.7%

Updated

10 Dec, 2024

Data

Company Financials +

Fresenius SE & Co. KGaA

XTRA:FRE Stock Report

Market Cap: €19.0b

FRE Stock Overview

A health care company, provides products and services for chronically ill patients. More details

FRE fundamental analysis
Snowflake Score
Valuation5/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 62.6% below our estimate of its fair value

Earnings are forecast to grow 36.95% per year

Analysts in good agreement that stock price will rise by 20.6%

Risk Analysis

Has a high level of debt


Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WA
Analyst Price Target
Consensus Narrative from 15 Analysts

Biopharma Innovations And Critical Growth Initiatives Propel Earnings And Margin Expansion

Key Takeaways Strategic initiatives focused on productivity and organic growth are expected to enhance operational efficiency and drive margin expansion. Successful biosimilar launches and market access efforts support sustained revenue growth and improved financial flexibility.
View narrative
€40.86
FV
17.1% undervalued intrinsic discount
2.59%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
6 days ago author updated this narrative
TO
Tokyo
Community Contributor

First comes the pain, then the money.

My main narrative for FRE: What former CEO Mark Schneider blow up to an inefficient giant, will now be cut down by actual CEO Michael Sen and trimmed on efficiency from formally 4 segments FMC (dialyses), Helios (private hospitals), Kabi(Generic & Infusions), Vamed (Projects & Digitalization) only 2 remain: Helios, Kabi, the other will be sold, and the intakes will help to restructure the financial situation under Mark Schneider the Spanish hospitals were acquired, this was a good deal: privat hospital runs well in Spain, because of their good reputation wealthy Latin Americans travel for medical treatments to Spain I focus also on: More equity than debt. Ratio is at 62% (debt/equity).
View narrative
€74.00
FV
54.2% undervalued intrinsic discount
24.16%
Revenue growth p.a.
3users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
5 months ago author updated this narrative

Fresenius SE & Co. KGaA Competitors

Fresenius Medical Care

XTRA:FME

€13.4b

SYNLAB

HMSE:SYAB

€2.5b

Siemens Healthineers

XTRA:SHL

€59.9b

Labcorp Holdings

NYSE:LH

US$19.5b

Price History & Performance

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price€33.89
52 Week High€36.24
52 Week Low€24.32
Beta1.04
11 Month Change0.12%
3 Month Change0.18%
1 Year Change19.67%
33 Year Change-0.26%
5 Year Change-32.22%
Change since IPO2,901.79%

Recent News & Updates

Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult

Nov 29
Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Recent updates

Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult

Nov 29
Getting In Cheap On Fresenius SE & Co. KGaA (ETR:FRE) Might Be Difficult

Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Sep 18
Fresenius SE KGaA (ETR:FRE) Is Finding It Tricky To Allocate Its Capital

Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Sep 03
Is There Now An Opportunity In Fresenius SE & Co. KGaA (ETR:FRE)?

Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

Aug 19
Investors Still Waiting For A Pull Back In Fresenius SE & Co. KGaA (ETR:FRE)

We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Jul 15
We Think Fresenius SE KGaA (ETR:FRE) Is Taking Some Risk With Its Debt

Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

Jun 12
Fresenius SE KGaA (ETR:FRE) Has Some Difficulty Using Its Capital Effectively

At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

May 28
At €29.20, Is Fresenius SE & Co. KGaA (ETR:FRE) Worth Looking At Closely?

With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

May 02
With Fresenius SE & Co. KGaA (ETR:FRE) It Looks Like You'll Get What You Pay For

Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Mar 29
Does Fresenius SE KGaA (ETR:FRE) Have A Healthy Balance Sheet?

Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Mar 13
Fresenius SE KGaA (ETR:FRE) Could Be At Risk Of Shrinking As A Company

Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

Feb 06
Why Fresenius SE & Co. KGaA (ETR:FRE) Could Be Worth Watching

A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Jan 19
A Look At The Fair Value Of Fresenius SE & Co. KGaA (ETR:FRE)

Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Jan 03
Fresenius SE & Co. KGaA's (ETR:FRE) Shares Not Telling The Full Story

Shareholder Returns

FREDE HealthcareDE Market
7D0.06%2.7%2.1%
1Y19.7%18.8%9.3%

Return vs Industry: FRE matched the German Healthcare industry which returned 18.8% over the past year.

Return vs Market: FRE exceeded the German Market which returned 9.3% over the past year.

Price Volatility

Is FRE's price volatile compared to industry and market?
FRE volatility
FRE Average Weekly Movement2.7%
Healthcare Industry Average Movement4.1%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.7%
10% least volatile stocks in DE Market2.5%

Stable Share Price: FRE has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: FRE's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011177,091Michael Senwww.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Fresenius SE & Co. KGaA Fundamentals Summary

How do Fresenius SE KGaA's earnings and revenue compare to its market cap?
FRE fundamental statistics
Market cap€19.00b
Earnings (TTM)-€479.00m
Revenue (TTM)€22.81b

0.8x

P/S Ratio

-39.8x

P/E Ratio

Is FRE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FRE income statement (TTM)
Revenue€22.81b
Cost of Revenue€17.48b
Gross Profit€5.33b
Other Expenses€5.81b
Earnings-€479.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.85
Gross Margin23.37%
Net Profit Margin-2.10%
Debt/Equity Ratio60.9%

How did FRE perform over the long term?

See historical performance and comparison